The Cystic Fibrosis Foundation can help you engage people with cystic fibrosis so that you can incorporate their voices into the decision-making process throughout the development lifecycle of your
Site Search
The Carolyn and C. Richard Mattingly Leadership in Mental Health Care Award honors those who are committed to the mental health of people with cystic fibrosis.
Cystic fibrosis biological samples are available to qualified researchers to help develop promising new studies that will support CF research and aid in drug development and drug discovery.
The goal of the CFTR Chemical Compound program is to enable cystic fibrosis research scientists to test known cystic fibrosis transmembrane conductance regulator (CFTR) modulating compounds in different functional assays.
Every person has two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. A person must inherit two copies of the CFTR gene that contain mutations — one copy from each parent — to have cystic fibrosis.
In an international research project, scientists are examining cystic fibrosis transmembrane conductance regulator (CFTR) mutations to determine which ones cause CF and to provide additional information associated with these mutations. Their findings are available in an online searchable database.
Carrier (or genetic) testing not only plays a key role in the diagnosis of cystic fibrosis, but testing also allows parents to find out what their chances are of having a child with CF to help inform important family planning decisions.
The objective of this award is to support excellent cystic fibrosis-related research projects that have been approved by the National Institutes of Health (or governmental funding agencies in other countries) but cannot be supported by available funds.
This program is intended to introduce students to cystic fibrosis research and encourage them to remain engaged in the field.
There are two main types of clinical studies in CF research. Both are important to move research forward and provide the best outcomes for people with CF.